Logical Analysis Report
Key Focus
- Moderna reports positive data on early-stage coronavirus vaccine trial, shares surge
Mderna's closely watched early-stage human trial for a coronavirus vaccine produced Covid-19 antibodies in all 45 participants, the biotech company announced Monday, sending the company's shares surging more than 17%.
Each participant received a 25, 100 or 250 microgram dose, with 15 people in each dose group - Data on neutralizing antibodies for the other participants were not yet available, Moderna said.
"These interim Phase 1 data, while early, demonstrate that vaccination with mRNA-1273 elicits an immune response of the magnitude caused by natural infection starting with a dose as low as 25 [micrograms]," Moderna chief medical officer Dr. Tal Zaks said in a statement.
"When combined with the success in preventing viral replication in the lungs of a pre-clinical challenge model at a dose that elicited similar levels of neutralizing antibodies, these data substantiate our belief that mRNA-1273 has the potential to prevent COVID-19 disease and advance our ability to select a dose for pivotal trials," Zaks added.
Moderna CEO on the promising preliminary results of early-stage Covid-19 study
Scientists hope the antibodies provide some degree of protection against getting Covid-19, but they can't say that definitively yet since it hasn't been studied and some patients appear to have been reinfected after recovering from the virus.
There are no formally approved treatments for Covid-19, which has killed at least 315,225 and sickened 4.7 million people worldwide since emerging from the Chinese city of Wuhan more than four months ago, according to Johns Hopkins University
To understand how to read this report, please click here
Knowledge Graph(Read more)
Complex Event Analysis(Read more)
High Level Topics
VACCINECOVID-19MODERNAHigh Level Abstractions
VACCINE(4, 0 Order)( VACCINE )(4, 0 Order) top( VACCINE, COVID-19 )(3, 1st Order) top( VACCINE, COVID-19, ANTIBODIES )(2, 2nd Order) top( VACCINE, COVID-19, MODERNA )(1, 2nd Order) top( VACCINE, COVID-19, EARLY-STAGE )(2, 2nd Order) top( VACCINE, COVID-19, MRNA-1273 )(1, 2nd Order) top( VACCINE, COVID-19, CORONAVIRUS )(1, 2nd Order) top( VACCINE, COVID-19, ZAKS )(1, 2nd Order) top( VACCINE, COVID-19, WUHAN )(1, 2nd Order) top( VACCINE, ANTIBODIES )(3, 1st Order) top( VACCINE, ANTIBODIES, MODERNA )(1, 2nd Order) top( VACCINE, ANTIBODIES, MRNA-1273 )(1, 2nd Order) top( VACCINE, ANTIBODIES, MICROGRAM )(2, 2nd Order) top( VACCINE, ANTIBODIES, EARLY-STAGE )(2, 2nd Order) top( VACCINE, ANTIBODIES, CORONAVIRUS )(1, 2nd Order) top( VACCINE, ANTIBODIES, ZAKS )(1, 2nd Order) top( VACCINE, MODERNA )(2, 1st Order) top( VACCINE, EARLY-STAGE )(2, 1st Order) top( VACCINE, CORONAVIRUS )(2, 1st Order) top( VACCINE, VACCINES )(2, 1st Order) top( VACCINE, MRNA-1273 )(1, 1st Order) top( VACCINE, MICROGRAM )(2, 1st Order) topCOVID-19(4, 0 Order)( COVID-19 )(4, 0 Order) top( COVID-19, ANTIBODIES )(3, 1st Order) top( COVID-19, ANTIBODIES, MODERNA )(1, 2nd Order) top( COVID-19, ANTIBODIES, MICROGRAM )(2, 2nd Order) top( COVID-19, ANTIBODIES, EARLY-STAGE )(2, 2nd Order) top( COVID-19, ANTIBODIES, MRNA-1273 )(1, 2nd Order) top( COVID-19, ANTIBODIES, MICROGRAMS )(1, 2nd Order) top( COVID-19, ANTIBODIES, CORONAVIRUS )(1, 2nd Order) top( COVID-19, MODERNA )(1, 1st Order) top( COVID-19, MICROGRAM )(2, 1st Order) top( COVID-19, EARLY-STAGE )(2, 1st Order) top( COVID-19, MICROGRAMS )(1, 1st Order) top( COVID-19, CORONAVIRUS )(1, 1st Order) top( COVID-19, ZAKS )(1, 1st Order) topMODERNA(2, 0 Order)( MODERNA )(2, 0 Order) topReferences- ( VACCINE ) top
- ( VACCINE, COVID-19 ) top
- ( VACCINE, COVID-19, ANTIBODIES ) top
- (Read more) top Moderna reports positive data on early-stage coronavirus vaccine trial, shares surge
Mderna's closely watched early-stage human trial for a coronavirus vaccine produced Covid-19 antibodies in all 45 participants, the biotech company announced Monday, sending the company's shares surging more than 17%.
Each participant received a 25, 100 or 250 microgram dose, with 15 people... - (Read more) topData on neutralizing antibodies for the other participants were not yet available, Moderna said.
"These interim Phase 1 data, while early, demonstrate that vaccination with mRNA-1273 elicits an immune response of the magnitude... - ( VACCINE, COVID-19, MODERNA ) top
- (Read more) topData on neutralizing antibodies for the other participants were not yet available, Moderna said.
"These interim Phase 1 data, while early, demonstrate that vaccination with mRNA-1273 elicits an immune response of the magnitude caused by natural infection starting with a dose as... - ( VACCINE, COVID-19, EARLY-STAGE ) top
- (Read more) top Moderna reports positive data on early-stage coronavirus vaccine trial, shares surge
Mderna's closely watched early-stage human trial for a coronavirus vaccine produced Covid-19 antibodies in all 45 participants, the biotech company... - (Read more) top
Moderna CEO on the promising preliminary results of early-stage Covid-19 study
Scientists hope the antibodies provide some degree of protection against getting Covid-19, but they can't say that definitively yet since it hasn't been studied and some patients... - ( VACCINE, COVID-19, MRNA-1273 ) top
- (Read more) top
"These interim Phase 1 data, while early, demonstrate that vaccination with mRNA-1273 elicits an immune response of the magnitude caused by natural infection starting with a dose as low as 25 [micrograms]," Moderna chief medical officer Dr. Tal Zaks said in a statement.
"When... - ( VACCINE, COVID-19, CORONAVIRUS ) top
- (Read more) top Moderna reports positive data on early-stage coronavirus vaccine trial, shares surge
Mderna's closely watched early-stage human trial for a coronavirus vaccine produced Covid-19 antibodies in all 45 participants, the biotech company announced Monday,... - ( VACCINE, COVID-19, ZAKS ) top
- (Read more) top... similar levels of neutralizing antibodies, these data substantiate our belief that mRNA-1273 has the potential to prevent COVID-19 disease and advance our ability to select a dose for pivotal trials," Zaks added.
Moderna CEO on the promising preliminary results of early-stage Covid-19 study
Scientists hope the antibodies provide some degree of protection against getting Covid-19, but they... - ( VACCINE, COVID-19, WUHAN ) top
- (Read more) top
There are no formally approved treatments for Covid-19, which has killed at least 315,225 and sickened 4.7 million people worldwide since emerging from the Chinese city of Wuhan more than four months ago, according to Johns Hopkins University. - ( VACCINE, ANTIBODIES ) top
- ( VACCINE, ANTIBODIES, MODERNA ) top
- (Read more) topSee ( VACCINE , COVID-19 , MODERNA )
- ( VACCINE, ANTIBODIES, MRNA-1273 ) top
- (Read more) topSee ( VACCINE , COVID-19 , MRNA-1273 )
- ( VACCINE, ANTIBODIES, MICROGRAM ) top
- (Read more) top
Each participant received a 25, 100 or 250 microgram dose, with 15 people in each dose group. - (Read more) top
At day 43, or two weeks following the second dose, levels of binding antibodies in the 25 microgram group were at the levels generally seen in blood samples from people who recovered from the disease, the company said - ( VACCINE, ANTIBODIES, EARLY-STAGE ) top
- (Read more) topSee ( VACCINE , COVID-19 , EARLY-STAGE )
- ( VACCINE, ANTIBODIES, CORONAVIRUS ) top
- (Read more) topSee ( VACCINE , COVID-19 , CORONAVIRUS )
- ( VACCINE, ANTIBODIES, ZAKS ) top
- (Read more) topSee ( VACCINE , COVID-19 , ZAKS )
- ( VACCINE, MODERNA ) top
- (Read more) topSee ( VACCINE , COVID-19 , MODERNA )
- (Read more) top
Earlier this month, Moderna announced that it was wrapping up phase one human trials on its potential vaccine with the U.S. government and is moving to start phase two trials that would include 600 participants - ( VACCINE, EARLY-STAGE ) top
- (Read more) topSee ( VACCINE , COVID-19 , EARLY-STAGE )
- ( VACCINE, CORONAVIRUS ) top
- (Read more) topSee ( VACCINE , COVID-19 , CORONAVIRUS )
- (Read more) top
Moderna, which has been fast-tracking work with the National Institutes of Health to develop a vaccine, is the first company to release data on a human trial testing a coronavirus vaccine.
The company said it expects to begin a phase 3 trial in July.
Earlier this month, Moderna announced that it was wrapping up phase one human trials on its potential vaccine with... - ( VACCINE, VACCINES ) top
- (Read more) top
More than 100 vaccines are under development globally, according to the World Health Organization. - (Read more) topAt least eight vaccines are in human trials.
Moderna, which has been fast-tracking work with the National Institutes of Health to develop a vaccine, is the first company to release data on a human trial testing a coronavirus... - ( VACCINE, MRNA-1273 ) top
- (Read more) topSee ( VACCINE , COVID-19 , MRNA-1273 )
- ( VACCINE, MICROGRAM ) top
- (Read more) topSee ( VACCINE , ANTIBODIES , MICROGRAM )
- ( COVID-19 ) top
- ( COVID-19, ANTIBODIES ) top
- ( COVID-19, ANTIBODIES, MODERNA ) top
- (Read more) topSee ( VACCINE , COVID-19 , MODERNA )
- ( COVID-19, ANTIBODIES, MICROGRAM ) top
- (Read more) topSee ( VACCINE , ANTIBODIES , MICROGRAM )
- (Read more) topData on a second dose was not available for the 250 microgram group, the company said.
The vaccine also produced neutralizing antibodies against Covid-19 in at least eight participants, the company said - ( COVID-19, ANTIBODIES, EARLY-STAGE ) top
- (Read more) topSee ( VACCINE , COVID-19 , EARLY-STAGE )
- ( COVID-19, ANTIBODIES, MRNA-1273 ) top
- (Read more) topSee ( VACCINE , COVID-19 , MRNA-1273 )
- ( COVID-19, ANTIBODIES, MICROGRAMS ) top
- (Read more) top
Four participants were assigned to receive a 25 microgram dose, while the other four received 100 micrograms. - ( COVID-19, ANTIBODIES, CORONAVIRUS ) top
- (Read more) topSee ( VACCINE , COVID-19 , CORONAVIRUS )
- ( COVID-19, MODERNA ) top
- (Read more) topSee ( VACCINE , COVID-19 , MODERNA )
- ( COVID-19, MICROGRAM ) top
- (Read more) topSee ( VACCINE , ANTIBODIES , MICROGRAM )
- (Read more) topSee ( COVID-19 , ANTIBODIES , MICROGRAM )
- ( COVID-19, EARLY-STAGE ) top
- (Read more) topSee ( VACCINE , COVID-19 , EARLY-STAGE )
- ( COVID-19, MICROGRAMS ) top
- (Read more) topSee ( COVID-19 , ANTIBODIES , MICROGRAMS )
- ( COVID-19, CORONAVIRUS ) top
- (Read more) topSee ( VACCINE , COVID-19 , CORONAVIRUS )
- ( COVID-19, ZAKS ) top
- (Read more) topSee ( VACCINE , COVID-19 , ZAKS )
- ( MODERNA ) top
- (Read more) topLevels of neutralizing antibodies were at or above levels seen in blood samples, the company said. Data on neutralizing antibodies for the other participants were not yet available, Moderna said.
"These interim Phase 1 data, while early, demonstrate that vaccination with mRNA-1273 elicits an immune response of the magnitude caused by natural infection starting with a dose as...
- (Read more) top... develop a vaccine, is the first company to release data on a human trial testing a coronavirus vaccine.
The company said it expects to begin a phase 3 trial in July.
Earlier this month, Moderna announced that it was wrapping up phase one human trials on its potential vaccine with the U.S. government and is moving to start phase two trials that would include 600 participants